Abstract | BACKGROUND: AIM: METHODS: RESULTS: Within 8 weeks, 10 of 20 (50%) patients achieved clinical remission (seven of 13 moderate, and three of seven severe). At 24 weeks, 13 of 20 (65%) patients were in clinical remission. Five patients required colectomy (four severe, one moderate ulcerative colitis) and one required rescue ciclosporin (moderate ulcerative colitis). Two patients developed herpes zoster, but treatment was generally well tolerated. CONCLUSIONS:
|
Authors | T J Creed, C S J Probert, M N Norman, M Moorghen, N A Shepherd, S D Hearing, C M Dayan, BASBUC INVESTIGATORS |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 23
Issue 10
Pg. 1435-42
(May 15 2006)
ISSN: 0269-2813 [Print] England |
PMID | 16669958
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Immunosuppressive Agents
- Receptors, Interleukin-2
- Recombinant Fusion Proteins
- Cyclosporine
- Basiliximab
- Prednisolone
|
Topics |
- Adolescent
- Adult
- Aged
- Anti-Inflammatory Agents
(administration & dosage)
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Basiliximab
- Colectomy
- Colitis, Ulcerative
(drug therapy, surgery)
- Cyclosporine
(administration & dosage)
- Drug Administration Schedule
- Female
- Humans
- Immunosuppressive Agents
(administration & dosage, adverse effects)
- Infusions, Intravenous
- Male
- Middle Aged
- Prednisolone
(administration & dosage)
- Quality of Life
- Receptors, Interleukin-2
(antagonists & inhibitors)
- Recombinant Fusion Proteins
(administration & dosage, adverse effects)
- Severity of Illness Index
- Treatment Outcome
|